July/August 2015

An estimation of the direct healthcare and indirect work-loss cost burden of chronic HCV using health insurance claims covering 13 million individuals.

In outpatients with type 2 diabetes mellitus, persistent exenatide treatment lowered glycated hemoglobin and hyperglycemia in both genders. Waist circumference and body weight were more reduced in women.

Adherence classes were determined for patients taking multiple medications (ie, lipid-lowering, antihypertensive, antidiabetic) and were found to be related to serum profiles and risk of adverse events.

The cost of life-saving medications and the meaning of value are discussed.

Incorporating patient-related sociodemographic factors into performance measurement systems is essential for providing an accurate assessment of the quality of care delivered.

E-prescribing adoption has increased dramatically over the past decade. This study provides empirical evidence that utilization among adopters continues to increase, suggesting application “stickiness.”

With continued increases in the US drug spend, the evolution of fully transparent PBM programs has introduced an alternative approach to traditional PBM structures aimed at enhanced utilization and cost control.

This study assesses the preferences of patients with cystic fibrosis for treatments that differ in the mode of administration.

Which states can policy makers look to as leaders in creating patient-focused health insurance markets? A series of state-by-state progress reports holds the answer.